Alliance Pharmaceutical Corp.

Peter E Keipert

Nicholas Simon Faithfull

Duane J Roth

Jean G Riess

Ronald M Hopkins

Thomas F Zuck

Ernest George Schutt

Jeffry G Weers

Stephen F Flaim

Gwen H Rosenberg

Timothy J Pelura

N Simon Faithfull

A method of ameliorating tissue damage resulting from hypoxia or ischemia by administering systemically a synthetic oxygen carrier to an individual having or suspected of having blood vessel obstruction is disclosed. A synthetic oxygen carrier in a physiologically acceptable vehicle, wherein the synthetic oxygen carrier comprises submicron sized particles capable of passing through emboli-obstructed blood vessels is also disclosed.

Amelioration of ischemic damage using synthetic oxygen carriers

A method for treating conditions associated with ischemia or infarct is disclosed which includes the steps of administering a biocompatible non-blood oxygen carrier while monitoring one or more oxygenation indices to maintain oxygenation of the patient's tissues at or above a predetermined level.

Method for the treatment of organ ischemia or infarct comprising

A method for hemodiluting a patient is disclosed which includes the steps of administering a biocompatible oxygen carrier in conjunction with surgery or organ ischemia or infarct while assessing the patient's PvO.sub.2 or other oxygenation indices, and administering to the patient additional oxygen carrier or autologous blood in response to the PvO.sub.2 value if necessary to maintain the PvO.sub.2 at or above the desired level.

Method of hemodilution facilitated by monitoring oxygenation status

A fluorocarbon emulsion which exhibits reduced pulmonary gas-trapping properties in species-sensitive laboratory animals is disclosed. Additionally, the fluorocarbon component(s) exhibit short organ retention time(s). The emulsion includes an aqueous phase, an emulsifier, and a fluorocarbon (or fluorocarbon composition), having a vapor pressure of less than about 8 torr to reduce pulmonary gas-trapping, and having an organ retention half life of less than about 6 weeks and more preferably less than about 3 to 4 weeks.

Fluorocarbon emulsions with reduced pulmonary gas-trapping properties

A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of removing and preferably storing a portion of the patient's blood, intravenously administering a biocompatible liquid in sufficient quantity to substantially maintain the patient's hemodynamic stability, wherein the liquid comprises an effective oxygen-delivery enhancing amount of a biocompatible synthetic oxygen carrier, after which the patient undergoes a loss of blood, and then readministering blood to the patient, preferably the stored blood. In one embodiment, the biocompatible liquid further comprises a hemodiluent and the hemodiluent is administered separately from the oxygen carrier.

Growing community of inventors

San Diego, CA, United States of America

Peter E Keipert